Back to Search
Start Over
Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus:Impact of Hepatitis C Virus Treatment
- Source :
- Mocroft , A , Lundgren , J , Gerstoft , J , Rasmussen , L D , Bhagani , S , Aho , I , Pradier , C , Bogner , J R , Mussini , C , Uberti Foppa , C , Maltez , F , Laguno , M , Wandeler , G , Falconer , K , Trofimova , T , Borodulina , E , Jevtovic , D , Bakowska , E , Kase , K , Kyselyova , G , Haubrich , R , Rockstroh , J K , Peters , L , EuroSIDA Study , Losso , M , Kundro , M , Schmied , B , Kronborg , G , Benfield , T , Katzenstein , T L , Pedersen , C , Johansen , I S , Østergaard , L , Wiese , L , Møller , N F , Nielsen , L N , Scullard , G , Clarke , A & Leen , C 2020 , ' Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus : Impact of Hepatitis C Virus Treatment ' , Clinical Infectious Diseases , vol. 70 , no. 10 , pp. 2131-2140 .
- Publication Year :
- 2020
-
Abstract
- BACKGROUND: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear.METHODS: People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD).RESULTS: There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured.CONCLUSIONS: Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD.
Details
- Database :
- OAIster
- Journal :
- Mocroft , A , Lundgren , J , Gerstoft , J , Rasmussen , L D , Bhagani , S , Aho , I , Pradier , C , Bogner , J R , Mussini , C , Uberti Foppa , C , Maltez , F , Laguno , M , Wandeler , G , Falconer , K , Trofimova , T , Borodulina , E , Jevtovic , D , Bakowska , E , Kase , K , Kyselyova , G , Haubrich , R , Rockstroh , J K , Peters , L , EuroSIDA Study , Losso , M , Kundro , M , Schmied , B , Kronborg , G , Benfield , T , Katzenstein , T L , Pedersen , C , Johansen , I S , Østergaard , L , Wiese , L , Møller , N F , Nielsen , L N , Scullard , G , Clarke , A & Leen , C 2020 , ' Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus : Impact of Hepatitis C Virus Treatment ' , Clinical Infectious Diseases , vol. 70 , no. 10 , pp. 2131-2140 .
- Notes :
- application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1263226021
- Document Type :
- Electronic Resource